{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:46:31Z","timestamp":1777005991852,"version":"3.51.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1038\/ncponc0558","type":"journal-article","created":{"date-parts":[[2006,8,8]],"date-time":"2006-08-08T09:25:23Z","timestamp":1155029123000},"page":"448-457","source":"Crossref","is-referenced-by-count":575,"title":["Mechanisms of Disease: oncogene addiction\u2014a rationale for molecular targeting in cancer therapy"],"prefix":"10.1038","volume":"3","author":[{"given":"I Bernard","family":"Weinstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew K","family":"Joe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncponc0558_CR1","first-page":"2696","volume":"3","author":"IB Weinstein","year":"1997","unstructured":"Weinstein IB  et al. (1997) Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res 3: 2696\u20132702","journal-title":"Clin Cancer Res"},{"key":"BFncponc0558_CR2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/carcin\/21.5.857","volume":"21","author":"IB Weinstein","year":"2000","unstructured":"Weinstein IB (2000) Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21: 857\u2013864","journal-title":"Carcinogenesis"},{"key":"BFncponc0558_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.1073096","volume":"297","author":"IB Weinstein","year":"2002","unstructured":"Weinstein IB (2002) Cancer. Addiction to oncogenes\u2014the Achilles heal of cancer. Science 297: 63\u201364","journal-title":"Science"},{"key":"BFncponc0558_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nature03095","volume":"432","author":"C Sawyers","year":"2004","unstructured":"Sawyers C (2004) Targeted cancer therapy. Nature 432: 294\u2013297","journal-title":"Nature"},{"key":"BFncponc0558_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrc1691","volume":"5","author":"WG Kaelin Jr","year":"2005","unstructured":"Kaelin WG Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5: 689\u2013698","journal-title":"Nat Rev Cancer"},{"key":"BFncponc0558_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1097-2765(00)80367-6","volume":"4","author":"DW Felsher","year":"1999","unstructured":"Felsher DW and Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4: 199\u2013207","journal-title":"Mol Cell"},{"key":"BFncponc0558_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/71691","volume":"24","author":"CS Huettner","year":"2000","unstructured":"Huettner CS  et al. (2000) Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 24: 57\u201360","journal-title":"Nat Genet"},{"key":"BFncponc0558_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/22788","volume":"400","author":"L Chin","year":"1999","unstructured":"Chin L  et al. (1999) Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468\u2013472","journal-title":"Nature"},{"key":"BFncponc0558_CR9","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1101\/gad.943001","volume":"15","author":"EL Jackson","year":"2001","unstructured":"Jackson EL  et al. (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243\u20133248","journal-title":"Genes Dev"},{"key":"BFncponc0558_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0092-8674(02)00738-9","volume":"109","author":"S Pelengaris","year":"2002","unstructured":"Pelengaris S  et al. (2002) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321\u2013334","journal-title":"Cell"},{"key":"BFncponc0558_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1126\/science.1071489","volume":"297","author":"M Jain","year":"2002","unstructured":"Jain M  et al. (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297: 102\u2013104","journal-title":"Science"},{"key":"BFncponc0558_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1535-6108(02)00212-X","volume":"2","author":"SE Moody","year":"2002","unstructured":"Moody SE  et al. (2002) Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2: 451\u2013461","journal-title":"Cancer Cell"},{"key":"BFncponc0558_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ccr.2005.07.009","volume":"8","author":"SE Moody","year":"2005","unstructured":"Moody SE  et al. (2005) The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8: 197\u2013209","journal-title":"Cancer Cell"},{"key":"BFncponc0558_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/84691","volume":"7","author":"CM D'Cruz","year":"2001","unstructured":"D'Cruz CM  et al. (2001) c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7: 235\u2013239","journal-title":"Nat Med"},{"key":"BFncponc0558_CR15","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1101\/gad.1051603","volume":"17","author":"EJ Gunther","year":"2003","unstructured":"Gunther EJ  et al. (2003) Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 17: 488\u2013501","journal-title":"Genes Dev"},{"key":"BFncponc0558_CR16","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/bjc.1994.405","volume":"70","author":"R Colomer","year":"1994","unstructured":"Colomer R  et al. (1994) erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 70: 819\u2013825","journal-title":"Br J Cancer"},{"key":"BFncponc0558_CR17","first-page":"571","volume":"11","author":"P Zhou","year":"1995","unstructured":"Zhou P  et al. (1995) Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 11: 571\u2013580","journal-title":"Oncogene"},{"key":"BFncponc0558_CR18","first-page":"1569","volume":"57","author":"N Arber","year":"1997","unstructured":"Arber N  et al. (1997) Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 57: 1569\u20131574","journal-title":"Cancer Res"},{"key":"BFncponc0558_CR19","first-page":"3505","volume":"59","author":"M Kornmann","year":"1999","unstructured":"Kornmann, M  et al. (1999) Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res 59: 3505\u20133511","journal-title":"Cancer Res"},{"key":"BFncponc0558_CR20","first-page":"4876","volume":"59","author":"ER Sauter","year":"1999","unstructured":"Sauter ER  et al. (1999) Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res 59: 4876\u20134881","journal-title":"Cancer Res"},{"key":"BFncponc0558_CR21","doi-asserted-by":"publisher","first-page":"8125","DOI":"10.1158\/0008-5472.CAN-05-0648","volume":"65","author":"AB Hui","year":"2005","unstructured":"Hui AB  et al. (2005) Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res 65: 8125\u20138133","journal-title":"Cancer Res"},{"key":"BFncponc0558_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/(SICI)1098-2744(199710)20:2<251::AID-MC12>3.0.CO;2-9","volume":"20","author":"K Aoki","year":"1997","unstructured":"Aoki K  et al. (1997) Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol Carcinog 20: 251\u2013258","journal-title":"Mol Carcinog"},{"key":"BFncponc0558_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1535-6108(02)00122-8","volume":"2","author":"TR Brummelkamp","year":"2002","unstructured":"Brummelkamp TR  et al. (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2: 243\u2013247","journal-title":"Cancer Cell"},{"key":"BFncponc0558_CR24","first-page":"1291","volume":"9","author":"UN Verma","year":"2003","unstructured":"Verma UN  et al. (2003) Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 9: 1291\u20131300","journal-title":"Clin Cancer Res"},{"key":"BFncponc0558_CR25","first-page":"3593","volume":"63","author":"K Li","year":"2003","unstructured":"Li K  et al. (2003) Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res 63: 3593\u20133597","journal-title":"Cancer Res"},{"key":"BFncponc0558_CR26","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-04-2423","volume":"65","author":"A Sharma","year":"2005","unstructured":"Sharma A  et al. (2005) Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65: 2412\u20132421","journal-title":"Cancer Res"},{"key":"BFncponc0558_CR27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1158\/0008-5472.CAN-03-2440","volume":"64","author":"AJ Miller","year":"2004","unstructured":"Miller AJ  et al. (2004) Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res 64: 509\u2013516","journal-title":"Cancer Res"},{"key":"BFncponc0558_CR28","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ  et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783\u2013792","journal-title":"N Engl J Med"},{"key":"BFncponc0558_CR29","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ  et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659\u20131672","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"BFncponc0558_CR30","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1093\/annonc\/12.suppl_1.S35","volume":"12","author":"J Baselga","year":"2001","unstructured":"Baselga J and Albanell J (2001) Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12 (Suppl 1): S35\u2013S41","journal-title":"Ann Oncol"},{"key":"BFncponc0558_CR31","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP  et al. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349: 1423\u20131432","journal-title":"N Engl J Med"},{"key":"BFncponc0558_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA  et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123\u2013132","journal-title":"N Engl J Med"},{"key":"BFncponc0558_CR33","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD  et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472\u2013480","journal-title":"N Engl J Med"},{"key":"BFncponc0558_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1053\/j.seminoncol.2005.07.017","volume":"32","author":"MJ Moore","year":"2005","unstructured":"Moore MJ (2005) Brief communication: a new combination in the treatment of advanced pancreatic cancer. Semin Oncol 32: 5\u20136","journal-title":"Semin Oncol"},{"key":"BFncponc0558_CR35","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-04-2618","volume":"11","author":"M Taron","year":"2005","unstructured":"Taron M  et al. (2005) Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11: 5878\u20135885","journal-title":"Clin Cancer Res"},{"key":"BFncponc0558_CR36","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ  et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129\u20132139","journal-title":"N Engl J Med"},{"key":"BFncponc0558_CR37","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao W  et al. (2004) EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306\u201313311","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncponc0558_CR38","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1056\/NEJMoa051918","volume":"353","author":"IK Mellinghoff","year":"2005","unstructured":"Mellinghoff IK  et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012\u20132024","journal-title":"N Engl J Med"},{"key":"BFncponc0558_CR39","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1200\/JCO.2005.07.119","volume":"23","author":"J Baselga","year":"2005","unstructured":"Baselga J  et al. (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and\/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23: 5568\u20135577","journal-title":"J Clin Oncol"},{"key":"BFncponc0558_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D  et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337\u2013345","journal-title":"N Engl J Med"},{"key":"BFncponc0558_CR41","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","volume":"23","author":"KD Miller","year":"2005","unstructured":"Miller KD  et al. (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792\u2013799","journal-title":"J Clin Oncol"},{"key":"BFncponc0558_CR42","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H  et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335\u20132342","journal-title":"N Engl J Med"},{"key":"BFncponc0558_CR43","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC  et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427\u2013434","journal-title":"N Engl J Med"},{"key":"BFncponc0558_CR44","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME  et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876\u2013880","journal-title":"Science"},{"key":"BFncponc0558_CR45","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S  et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786\u2013792","journal-title":"N Engl J Med"},{"key":"BFncponc0558_CR46","first-page":"7149","volume":"62","author":"P La Rosee","year":"2002","unstructured":"La Rosee P  et al. (2002) Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec\u00ae, STI571). Cancer Res 62: 7149\u20137153","journal-title":"Cancer Res"},{"key":"BFncponc0558_CR47","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J","volume":"73","author":"JF Kerr","year":"1994","unstructured":"Kerr JF  et al. (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73: 2013\u20132026","journal-title":"Cancer"},{"key":"BFncponc0558_CR48","doi-asserted-by":"publisher","first-page":"10031","DOI":"10.1073\/pnas.191379498","volume":"98","author":"GB Mills","year":"2001","unstructured":"Mills GB  et al. (2001) Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP\/RAFT\/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 98: 10031\u201310033","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncponc0558_CR49","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1126\/science.1101637","volume":"305","author":"R Sordella","year":"2004","unstructured":"Sordella R  et al. (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163\u20131167","journal-title":"Science"},{"key":"BFncponc0558_CR50","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/jnci\/dji112","volume":"97","author":"F Cappuzzo","year":"2005","unstructured":"Cappuzzo F  et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643\u2013655","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0558_CR51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncponc0007","volume":"1","author":"JE Dowell","year":"2004","unstructured":"Dowell JE and Minna JD (2004) The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy. Nat Clin Pract Oncol 1: 2\u20133","journal-title":"Nat Clin Pract Oncol"},{"key":"BFncponc0558_CR52","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature02370","volume":"428","author":"PJ Paddison","year":"2004","unstructured":"Paddison PJ  et al. (2004) A resource for large-scale RNA-interference-based screens in mammals. Nature 428: 427\u2013431","journal-title":"Nature"},{"key":"BFncponc0558_CR53","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1158\/1535-7163.MCT-05-0106","volume":"4","author":"SZ Zhang","year":"2005","unstructured":"Zhang SZ  et al. (2005) Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther 4: 1577\u20131584","journal-title":"Mol Cancer Ther"},{"key":"BFncponc0558_CR54","doi-asserted-by":"publisher","first-page":"5713","DOI":"10.1038\/sj.onc.1208919","volume":"24","author":"AC Varga","year":"2005","unstructured":"Varga AC and Wrana JL (2005) The disparate role of BMP in stem cell biology. Oncogene 24: 5713\u20135721","journal-title":"Oncogene"},{"key":"BFncponc0558_CR55","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1002\/cncr.21453","volume":"104","author":"WM Stadler","year":"2005","unstructured":"Stadler WM (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 104: 2323\u20132333","journal-title":"Cancer"},{"key":"BFncponc0558_CR56","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature03664","volume":"436","author":"LA Garraway","year":"2005","unstructured":"Garraway LA  et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117\u2013122","journal-title":"Nature"},{"key":"BFncponc0558_CR57","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1126\/science.1073733","volume":"297","author":"DM Berman","year":"2002","unstructured":"Berman, DM  et al. (2002) Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297: 1559\u20131561","journal-title":"Science"},{"key":"BFncponc0558_CR58","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1126\/science.1104815","volume":"307","author":"F Radtke","year":"2005","unstructured":"Radtke F and Clevers H (2005) Self-renewal and cancer of the gut: two sides of a coin. Science 307: 1904\u20131909","journal-title":"Science"},{"key":"BFncponc0558_CR59","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/427399a","volume":"427","author":"JM Ottino","year":"2004","unstructured":"Ottino JM (2004) Engineering complex systems. Nature 427: 399","journal-title":"Nature"},{"key":"BFncponc0558_CR60","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1126\/science.1089118","volume":"301","author":"D Bray","year":"2003","unstructured":"Bray D (2003) Molecular networks: the top-down view. Science 301: 1864\u20131865","journal-title":"Science"},{"key":"BFncponc0558_CR61","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1126\/science.1089072","volume":"301","author":"U Alon","year":"2003","unstructured":"Alon U (2003) Biological networks: the tinkerer as an engineer. Science 301: 1866\u20131867","journal-title":"Science"},{"key":"BFncponc0558_CR62","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s001099900023","volume":"77","author":"S Huang","year":"1999","unstructured":"Huang S (1999) Gene expression profiling, genetic networks, and cellular states: an integrating concept for tumorigenesis and drug discovery. J Mol Med 77: 469\u2013480","journal-title":"J Mol Med"},{"issue":"Suppl 2","key":"BFncponc0558_CR63","doi-asserted-by":"publisher","first-page":"ii30","DOI":"10.1093\/annonc\/mdi728","volume":"16","author":"JP Baak","year":"2005","unstructured":"Baak JP  et al. (2005) Genomics and proteomics\u2014the way forward. Ann Oncol 16 (Suppl 2): ii30\u201344","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"BFncponc0558_CR64","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000086626","volume":"69","author":"C Wittekind","year":"2005","unstructured":"Wittekind C and Neid M (2005) Cancer invasion and metastasis. Oncology 69 (Suppl 1): 14\u201316","journal-title":"Oncology"},{"key":"BFncponc0558_CR65","doi-asserted-by":"publisher","first-page":"7482","DOI":"10.1038\/sj.onc.1209088","volume":"24","author":"JQ Cheng","year":"2005","unstructured":"Cheng JQ  et al. (2005) The Akt\/PKB pathway: molecular target for cancer drug discovery. Oncogene 24: 7482\u20137492","journal-title":"Oncogene"},{"key":"BFncponc0558_CR66","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrc1093","volume":"3","author":"G Bergers","year":"2003","unstructured":"Bergers G and Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401\u2013410","journal-title":"Nat Rev Cancer"},{"key":"BFncponc0558_CR67","first-page":"535","volume":"6","author":"J Jonkers","year":"2004","unstructured":"Jonkers J and Berns A (2004) Oncogene addiction: sometimes a temporary slavery. Cancer Cell 6: 535\u2013538","journal-title":"Cancer Cell"},{"key":"BFncponc0558_CR68","first-page":"8930","volume":"63","author":"QW Fan","year":"2003","unstructured":"Fan QW  et al. (2003) Combinatorial efficacy achieved through two-point blockade within a signaling pathway\u2014a chemical genetic approach. Cancer Res 63: 8930\u20138938","journal-title":"Cancer Res"},{"key":"BFncponc0558_CR69","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/437942a","volume":"437","author":"S Frantz","year":"2005","unstructured":"Frantz S (2005) Drug discovery: playing dirty. Nature 437: 942\u2013943","journal-title":"Nature"},{"key":"BFncponc0558_CR70","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc1716","volume":"5","author":"L Whitesell","year":"2005","unstructured":"Whitesell L and Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761\u2013772","journal-title":"Nat Rev Cancer"},{"key":"BFncponc0558_CR71","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","volume":"5","author":"J Adams","year":"2004","unstructured":"Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5: 417\u2013421","journal-title":"Cancer Cell"},{"key":"BFncponc0558_CR72","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/35101008","volume":"1","author":"F McCormick","year":"2001","unstructured":"McCormick F (2001) Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 1: 130\u2013141","journal-title":"Nat Rev Cancer"},{"key":"BFncponc0558_CR73","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature02625","volume":"429","author":"G Egger","year":"2004","unstructured":"Egger G  et al. (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457\u2013463","journal-title":"Nature"},{"key":"BFncponc0558_CR74","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1158\/1535-7163.MCT-05-0216","volume":"4","author":"C Balch","year":"2005","unstructured":"Balch C  et al. (2005) Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 4: 1505\u20131514","journal-title":"Mol Cancer Ther"},{"key":"BFncponc0558_CR75","first-page":"718","volume":"8","author":"V Sandor","year":"2002","unstructured":"Sandor V  et al. (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718\u2013728","journal-title":"Clin Cancer Res"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc0558","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0558.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0558.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:43:17Z","timestamp":1684442597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":75,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["BFncponc0558"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0558","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}